BMY
Bristol-Myers Squibb Co - Phase 3 Trials Met Primary Endpoint With Significant Acr20 Response
时间：2024-12-23 19:59:00 市场： 综合 美股
Bristol Myers Squibb Announces Positive Topline Results From Two Pivotal Phase 3 Trials Evaluating Sotyktu (Deucravacitinib) in Adults With Psoriatic Arthritis
时间：2024-12-23 19:59:00 市场： 美股 综合
Bristol-Myers Squibb Co: Sotyktu Was Well-Tolerated and Demonstrated Safety Consistent With Established Profile
时间：2024-12-23 19:59:00 市场： 美股 综合
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab) for the First-Line Treatment of Adult Patients With Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
时间：2024-12-23 19:45:00 市场： 美股 综合
Century Therapeutics- Bms Notified Co on Dec 12 to Terminate Collaboration Agreement With Century Therapeutics
时间：2024-12-14 06:03:04 市场： 综合 美股
Century Therapeutics - Termination Effective March 12, 2025
时间：2024-12-14 06:03:04 市场： 综合 美股
Bristol-Myers Squibb Co Files for Mixed Shelf; Size Not Disclosed - SEC Filing
时间：2024-12-14 05:17:51 市场： 美股 综合
Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at Ash 2024 With Long-Term Survival Data and Results From Expanding Pipeline
时间：2024-12-10 06:45:00 市场： 美股 综合
Bristol-Myers Squibb Co : Bernstein Raises Target Price to $62 From $56
时间：2024-11-26 18:20:02 市场： 美股 综合
Bristol Myers Squibb’s Presentations at Ash 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
时间：2024-11-19 19:59:01 市场： 美股 综合